ATP Cofactors

ATP Cofactors

Optimox4.8 (1,123 ratings)
Format:Tablet Quantity: 90 Tablet(s) · 90 servings
Goals
$34.99 $0.38 per serving

Product analysis

61 out of 100

ATP Cofactors offers reasonable value for its B-vitamin combination, but a cardiovascular benefit from its particular niacin preparation is not established.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality60

The niacin preparation is clearly identified, while the riboflavin form is less clearly disclosed. Naming the niacin form helps distinguish it from preparations with different effects.

Ingredient Transparency81

Ingredient amounts are disclosed and some forms are identified. Unspecified forms still limit like-for-like comparisons.

Value For Money70

The riboflavin comparison is competitive and the niacin comparison is reasonable. Together they support fair value for the ingredients provided.

Customer Satisfaction84

Customer feedback is strongly positive. A large review pool gives a broad view of satisfaction, though reviews do not establish health benefits.

Product Focus0

The formula is simple, but support for the cardiovascular purpose considered here is not established. That uncertainty does not show that the ingredients are clinically ineffective.

Format
Tablet
Container
90 Tablet(s)
Per serving
$0.38
Customer rating
4.8 · 1,123 ratings
Report analysis

Goals

Cardiovascular Support
Impact
Limited evidence
F Ingredient FitF PathwaysF EvidenceF Formulation Logic
Niacin · 500 mg

ATP Cofactors lists 500 mg of inositol hexanicotinate under niacin, but this preparation has no credited contribution to the cardiovascular markers considered here. Riboflavin is also listed, yet no target pathway receives support from a credited ingredient. That lack of credited support does not establish that the preparation is clinically ineffective.

How this product is rated for Cardiovascular Support

Ingredient fit28

Niacin is listed, but its inositol hexanicotinate preparation receives no cardiovascular contribution; riboflavin is an additional active.
Goal fit
The listed ingredients have links to other goals, while this preparation is not credited for cardiovascular focus.
Dose adequacy
Although 500 mg is declared, no cardiovascular dose contribution is credited to this preparation.

Pathways0

No target cardiovascular pathway receives support from a credited ingredient.
Depth
No pathway is supported by a credited ingredient.
Breadth
None of the three target pathways reaches the coverage level.

Evidence0

The supplied facts identify no credited ingredient at an effective dose or in a studied preparation for this goal.
Evidence strength
No credited ingredient reaches an effective dose for the goal markers.
Studied preparation
No credited ingredient is at an effective dose in a studied preparation for this goal.

Formulation logic35

No cardiovascular contributor is credited, though no ingredient conflict is flagged.
Partner coverage
No cardiovascular ingredient is credited, so no standalone contributor or needed partner is represented.
Conflicts
No ingredient combination is flagged as conflicting for this goal.
Effective doses
There is no credited cardiovascular ingredient to which the effective-dose threshold applies.
Study evidence
Niacin Supportive 136 studies
Heart Health
Impact
Limited evidence
F Ingredient FitF PathwaysF EvidenceF Formulation Logic
Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per servingScore
Riboflavin
100 mg 68
Niacin (Inositol Hexanicotinate)
500 mg 62
Adults 18–50 Dairy Free Sugar Free
Report overview
C- Active Ingredient Quality & BioavailabilityC+ Dose, Safety & Label TransparencyC Value
Each serving supplies 500 mg of niacin as inositol hexanicotinate. The whole-product serving costs about $0.39.
How this ingredient is rated

Active Ingredient Quality & Bioavailability57

The niacin source is inositol hexanicotinate, a distinct form of niacin.
Niacin Form & Goal Alignment
Inositol hexanicotinate is the identified niacin form.
Precursor Source Quality
The identified source is inositol hexanicotinate.

Dose, Safety & Label Transparency67

The serving lists 500 mg of niacin as inositol hexanicotinate. Inositol hexanicotinate is generally associated with less flushing; no no-flush claim is identified in the saved facts.
Clarity of Chemical Form
The niacin form is identified as inositol hexanicotinate.
Form-Specific Dosage Efficacy
The serving lists 500 mg of niacin.
Flush Risk & Safety Labeling
Inositol hexanicotinate is generally associated with less flushing; no no-flush claim is identified in the saved facts.

Value60

A whole-product serving costs about $0.39; the price covers the full product.
Price Per Effective Serving
A whole-product serving costs about $0.39; the price covers the full product.
Riboflavin · 100 mg OverallScore68
F Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyB+ Value
Each serving provides 100 mg of standard riboflavin, a high amount in the evaluation. A whole-product serving costs about $0.39.
How this ingredient is rated

Active Ingredient Quality & Bioavailability30

Standard riboflavin must be converted into active forms in the body.
Riboflavin Form Quality
Standard riboflavin must be converted into active forms in the body.

Dose, Safety & Label Transparency100

The serving provides 100 mg of riboflavin, a high amount in the evaluation. The phosphate-yield distinction does not apply to this form.
Dosage for Energy & Metabolism
The serving provides 100 mg of riboflavin, a high amount in the evaluation.
R5P Elemental Yield Transparency
The phosphate-yield distinction does not apply to standard riboflavin.
Additive Purity
No artificial colors, flavors or synthetic sweeteners were flagged in the available ingredient information.

Value80

A whole-product serving costs about $0.39.
Price per Serving Value
A whole-product serving costs about $0.39.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  2. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  3. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  4. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  5. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  6. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  7. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  8. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  9. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  10. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin